Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Oral, Dual-, and Triple-Action, and New Drug Formulations In 2019, Novo Nordisk introduced an oral semaglutide known as Rybelsus for type 2 diabetes and later oral Wegovy for weight management
Serious injuries and symptoms discussed in Wegovy and GLP-1 litigation may include: Gastroparesis or delayed gastric emptying Stomach paralysis symptoms, including nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down Ileus or intestinal blockage Bowel obstruction or pseudo-obstruction Persistent vomiting and dehydration Malnutrition or inability to tolerate normal food intake Severe abdominal pain requiring emergency care or hospitalization Pancreatitis, which has been reported as a risk signal in GLP-1 research NAION-related vision loss, which should be evaluated separately from gastrointestinal injury claims These allegations do not mean every patient who used Wegovy has a claim
AHAs and BHAs can make your skin more sensitive to the sun, which means more risk of dark spots and damage
Known for its dual-purpose use in managing type 2 diabetes and aiding weight management, semaglutide has garnered significant attention due to its efficacy and relatively manageable side effects
Severe abdominal pain that radiates to the back, nausea, or vomiting should be evaluated right away
